Document is current
Any future updates will be listed below
-
Authors
Wang, Yudong
Janku, Filip http://orcid.org/0000-0002-8123-4065
Piha-Paul, Sarina
Hess, Kenneth http://orcid.org/0000-0003-1377-6070
Broaddus, Russell
Liu, Lidong
Shi, Naiyi
Overman, Michael
Kopetz, Scott
Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Naing, Aung
Hong, David
Tsimberidou, Apostolia M.
Karp, Daniel
Yao, James
Fu, Siqing http://orcid.org/0000-0002-1933-0419
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited | Takeda Oncology
Takeda Pharmaceutical Company
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA016672)
- License Information
-
More Information
Article History
Received: 6 October 2019
Accepted: 13 January 2020
First Online: 20 February 2020
Competing interests
: The competing and non-financial interests of the authors are listed below. This study used MD Anderson’s Clinical Research Facility, which is supported by the NIH through MD Anderson’s Cancer Center Support Grant (P30CA016672). MD Anderson receives funds from Takeda Pharmaceutical Company and the National Institutes of Health/NCI (grant #P30CA016672), which in turn funded Dr. Fu’s research for this manuscript. Drs. Vivek Subbiah and David Hong have both received clinical trial research funding from Takeda Pharmaceutical Company and the NIH/NCI through MD Anderson. Drs. Filip Janku, Sarina Piha-Paul, Michael Overman, Russell Broaddus, Scott Kopetz, Aung Naing, Apostolia-Maria Tsimberidou, Daniel Karp, and James Yao receive partial funding for their clinic research from the NIH/NCI (grant #P30CA016672). All other authors have no competing interests to declare.
